Cristina Mastini, Marco Campisi, Enrico Patrucco, Giulia Mura, Antonio Ferreira, Carlotta Costa, Chiara Ambrogio, Giulia Germena, Cinzia Martinengo, Silvia Peola, Ines Mota, Elena Vissio, Luca Molinaro, Maddalena Arigoni, Martina Olivero, Raffaele Calogero, Nina Prokoph, Fabrizio Tabbò, Brent Shoji, Laurence Brugieres, Birgit Geoerger, Suzanne D Turner, Carlos Cuesta-Mateos, Deborah D'Aliberti, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini, Giorgio G Inghirami, Valeria Chiono, Roger D Kamm, Emilio Hirsch, Raphael Koch, David M Weinstock, Jon C Aster, Claudia Voena, Roberto Chiarle
Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in several ALK-driven tumors, but the development of resistance limits their long-term clinical impact. Although resistance mechanisms have been studied extensively in ALK-driven non-small cell lung cancer, they are poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL). Here, we identify a survival pathway supported by the tumor microenvironment that activates phosphatidylinositol 3-kinase γ (PI3K-γ) signaling through the C-C motif chemokine receptor 7 (CCR7)...
June 28, 2023: Science Translational Medicine